Prostaglandin A2 increases uveoscleral outflow and trabecular outflow facility in the cat

Carol B Toris, Michael E. Yablonski, Yun Liang Wang, Mieko Hayashi

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Prostaglandins (PG) are very effective ocular hypotensive agents. It is generally agreed that these drugs reduce intraocular pressure primarily by increasing uveoscleral outflow. They may also increase trabecular outflow facility though available evidence is less convincing. It has been hypothesized that PGs may increase facility of uveoscleral outflow in addition to their other mechanisms, but this has not yet been tested. To help clarify the ocular hypotensive mechanism of action of a derived PG of the A type, cats were treated twice daily for one week with PGA2 (0·01%) to one eye and vehicle to the other. Measurements were made of aqueous flow and outflow facility with fluorophotometry and of intraocular pressure with pneumatonometry. From these values, uveoscleral outflow was calculated. In addition, total outflow facility, uveoscleral outflow, and uveoscleral outflow facility were determined with invasive methods. PGA2 significantly reduced IOP by a mean of at least 4·7 mmHg in all experiments with all P-values less than 0·01. Compared with contralateral vehicle-treated control eyes, uveoscleral outflow in the treated eye was significantly (P < 0·05) increased by at least 50% using two different methods of measurement. Compared with baseline day, PGA2 significantly (P ≤ 0·05) increased aqueous flow by 1·8 μl min-1, fluorophotometric outflow facility by 0·36 μl min-1 mmHg-1 and fluorophotometric uveoscleral outflow by 2·0 μl min-1. Total outflow facility was not significantly different comparing treated with contralateral control eyes. Facility of uveoscleral outflow was ≤ 0·02 μl min-1 mmHg-1 for both control and treated eyes. It is concluded that PGA2 decreases IOP in cats by increasing uveoscleral outflow and trabecular outflow facility as measured with fluorophotometry. A significant increase in aqueous flow reduces the ocular hypotensive effect.

Original languageEnglish (US)
Pages (from-to)649-657
Number of pages9
JournalExperimental Eye Research
Volume61
Issue number6
DOIs
StatePublished - Jan 1 1995

Fingerprint

Cats
Fluorophotometry
Intraocular Pressure
Prostaglandins A
prostaglandin A2
Prostaglandins
Pharmaceutical Preparations

Keywords

  • aqueous
  • cats
  • facility
  • ocular
  • outflow
  • pressure
  • prostaglandins
  • trabecular
  • uveoscleral

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Prostaglandin A2 increases uveoscleral outflow and trabecular outflow facility in the cat. / Toris, Carol B; Yablonski, Michael E.; Wang, Yun Liang; Hayashi, Mieko.

In: Experimental Eye Research, Vol. 61, No. 6, 01.01.1995, p. 649-657.

Research output: Contribution to journalArticle

Toris, Carol B ; Yablonski, Michael E. ; Wang, Yun Liang ; Hayashi, Mieko. / Prostaglandin A2 increases uveoscleral outflow and trabecular outflow facility in the cat. In: Experimental Eye Research. 1995 ; Vol. 61, No. 6. pp. 649-657.
@article{de8584223b6647b880f709e0e04f7cf7,
title = "Prostaglandin A2 increases uveoscleral outflow and trabecular outflow facility in the cat",
abstract = "Prostaglandins (PG) are very effective ocular hypotensive agents. It is generally agreed that these drugs reduce intraocular pressure primarily by increasing uveoscleral outflow. They may also increase trabecular outflow facility though available evidence is less convincing. It has been hypothesized that PGs may increase facility of uveoscleral outflow in addition to their other mechanisms, but this has not yet been tested. To help clarify the ocular hypotensive mechanism of action of a derived PG of the A type, cats were treated twice daily for one week with PGA2 (0·01{\%}) to one eye and vehicle to the other. Measurements were made of aqueous flow and outflow facility with fluorophotometry and of intraocular pressure with pneumatonometry. From these values, uveoscleral outflow was calculated. In addition, total outflow facility, uveoscleral outflow, and uveoscleral outflow facility were determined with invasive methods. PGA2 significantly reduced IOP by a mean of at least 4·7 mmHg in all experiments with all P-values less than 0·01. Compared with contralateral vehicle-treated control eyes, uveoscleral outflow in the treated eye was significantly (P < 0·05) increased by at least 50{\%} using two different methods of measurement. Compared with baseline day, PGA2 significantly (P ≤ 0·05) increased aqueous flow by 1·8 μl min-1, fluorophotometric outflow facility by 0·36 μl min-1 mmHg-1 and fluorophotometric uveoscleral outflow by 2·0 μl min-1. Total outflow facility was not significantly different comparing treated with contralateral control eyes. Facility of uveoscleral outflow was ≤ 0·02 μl min-1 mmHg-1 for both control and treated eyes. It is concluded that PGA2 decreases IOP in cats by increasing uveoscleral outflow and trabecular outflow facility as measured with fluorophotometry. A significant increase in aqueous flow reduces the ocular hypotensive effect.",
keywords = "aqueous, cats, facility, ocular, outflow, pressure, prostaglandins, trabecular, uveoscleral",
author = "Toris, {Carol B} and Yablonski, {Michael E.} and Wang, {Yun Liang} and Mieko Hayashi",
year = "1995",
month = "1",
day = "1",
doi = "10.1016/S0014-4835(05)80015-6",
language = "English (US)",
volume = "61",
pages = "649--657",
journal = "Experimental Eye Research",
issn = "0014-4835",
publisher = "Academic Press Inc.",
number = "6",

}

TY - JOUR

T1 - Prostaglandin A2 increases uveoscleral outflow and trabecular outflow facility in the cat

AU - Toris, Carol B

AU - Yablonski, Michael E.

AU - Wang, Yun Liang

AU - Hayashi, Mieko

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Prostaglandins (PG) are very effective ocular hypotensive agents. It is generally agreed that these drugs reduce intraocular pressure primarily by increasing uveoscleral outflow. They may also increase trabecular outflow facility though available evidence is less convincing. It has been hypothesized that PGs may increase facility of uveoscleral outflow in addition to their other mechanisms, but this has not yet been tested. To help clarify the ocular hypotensive mechanism of action of a derived PG of the A type, cats were treated twice daily for one week with PGA2 (0·01%) to one eye and vehicle to the other. Measurements were made of aqueous flow and outflow facility with fluorophotometry and of intraocular pressure with pneumatonometry. From these values, uveoscleral outflow was calculated. In addition, total outflow facility, uveoscleral outflow, and uveoscleral outflow facility were determined with invasive methods. PGA2 significantly reduced IOP by a mean of at least 4·7 mmHg in all experiments with all P-values less than 0·01. Compared with contralateral vehicle-treated control eyes, uveoscleral outflow in the treated eye was significantly (P < 0·05) increased by at least 50% using two different methods of measurement. Compared with baseline day, PGA2 significantly (P ≤ 0·05) increased aqueous flow by 1·8 μl min-1, fluorophotometric outflow facility by 0·36 μl min-1 mmHg-1 and fluorophotometric uveoscleral outflow by 2·0 μl min-1. Total outflow facility was not significantly different comparing treated with contralateral control eyes. Facility of uveoscleral outflow was ≤ 0·02 μl min-1 mmHg-1 for both control and treated eyes. It is concluded that PGA2 decreases IOP in cats by increasing uveoscleral outflow and trabecular outflow facility as measured with fluorophotometry. A significant increase in aqueous flow reduces the ocular hypotensive effect.

AB - Prostaglandins (PG) are very effective ocular hypotensive agents. It is generally agreed that these drugs reduce intraocular pressure primarily by increasing uveoscleral outflow. They may also increase trabecular outflow facility though available evidence is less convincing. It has been hypothesized that PGs may increase facility of uveoscleral outflow in addition to their other mechanisms, but this has not yet been tested. To help clarify the ocular hypotensive mechanism of action of a derived PG of the A type, cats were treated twice daily for one week with PGA2 (0·01%) to one eye and vehicle to the other. Measurements were made of aqueous flow and outflow facility with fluorophotometry and of intraocular pressure with pneumatonometry. From these values, uveoscleral outflow was calculated. In addition, total outflow facility, uveoscleral outflow, and uveoscleral outflow facility were determined with invasive methods. PGA2 significantly reduced IOP by a mean of at least 4·7 mmHg in all experiments with all P-values less than 0·01. Compared with contralateral vehicle-treated control eyes, uveoscleral outflow in the treated eye was significantly (P < 0·05) increased by at least 50% using two different methods of measurement. Compared with baseline day, PGA2 significantly (P ≤ 0·05) increased aqueous flow by 1·8 μl min-1, fluorophotometric outflow facility by 0·36 μl min-1 mmHg-1 and fluorophotometric uveoscleral outflow by 2·0 μl min-1. Total outflow facility was not significantly different comparing treated with contralateral control eyes. Facility of uveoscleral outflow was ≤ 0·02 μl min-1 mmHg-1 for both control and treated eyes. It is concluded that PGA2 decreases IOP in cats by increasing uveoscleral outflow and trabecular outflow facility as measured with fluorophotometry. A significant increase in aqueous flow reduces the ocular hypotensive effect.

KW - aqueous

KW - cats

KW - facility

KW - ocular

KW - outflow

KW - pressure

KW - prostaglandins

KW - trabecular

KW - uveoscleral

UR - http://www.scopus.com/inward/record.url?scp=0029415179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029415179&partnerID=8YFLogxK

U2 - 10.1016/S0014-4835(05)80015-6

DO - 10.1016/S0014-4835(05)80015-6

M3 - Article

VL - 61

SP - 649

EP - 657

JO - Experimental Eye Research

JF - Experimental Eye Research

SN - 0014-4835

IS - 6

ER -